drugset / Trial / NCT00444951

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

NCT00444951

Phase 3 Completed 450 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine. This study will evaluate the booster administration of Menactra® (Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine) compared with Mencevax® (Meningococcal A, C, Y, and W 135 Polysaccharide vaccine)in terms of their serum bactericidal antibody responses.

Timeline

Start
2007-02
Primary completion
2008-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Menactra Vaccine 0.5 ml Intramuscular
Subject Mencevax Vaccine 0.5 ml Subcutaneous